Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
Objective During the first wave of the SARS-CoV-2 pandemic, management of anticoagulation therapy in hospitalized patients with atrial fibrillation (AF) was simplified to low-molecular-weight heparin (LMWH) followed by oral anticoagulation, mainly owing to the risk of drug–drug interactions. However...
Main Authors: | Pável Olivera, César Velásquez-Escandón, Desirée Campoy, Katia Flores, Tania Canals, Erik Johansson, María José Herranz, Laia Martínez, Juan José Cerezo-Manchado, Ramón Salinas |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/10760296231180865 |
Similar Items
-
The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation
by: O. O. Shakhmatova
Published: (2020-12-01) -
Risk management in patients with atrial fibrillation and comorbid conditions: potentialities of edoxaban
by: O. L. Barbarash, et al.
Published: (2020-11-01) -
Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
by: Daisuke Fukamachi, et al.
Published: (2022-01-01) -
Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry
by: Juan José Cerezo Manchado MD, PhD, et al.
Published: (2023-10-01) -
Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
by: Alejandro Bimbo Diaz, et al.
Published: (2023-09-01)